Navigation Links
Dual effect on tumor blood vessels
Date:5/31/2012

As soon as they have grown to pinhead size, tumors rely on the formation of new blood vessels a process which is scientifically called angiogenesis. Interfering with this process (antiangiogenesis) is considered to be a promising approach in cancer medicine. However, those drugs that are already available for preventing the sprouting of new blood capillaries have failed to fulfill the high expectations placed on them.

Medical researchers hope to increase the efficacy of antiangiogenic therapies by attacking angiogenesis from several angles. Currently available antiangiogenic drugs are directed against the VEGF growth factor, which induces the sprouting of new blood vessels. However, other important players in angiogenesis include two signaling molecules called angiopoietin-1 and angiopoietin-2. Ang-1 is responsible for vascular maturation, while Ang-2 is a functional antagonist of Ang-1. Both signaling molecules bind to the same receptor, Tie-2, on the surface of endothelial cells.

"There are already studies showing that Ang-2 is a suitable target of new therapies directed against the blood supply of tumors. Combinations with already approved antiangiogenic drugs are regarded as particularly promising," says Prof. Dr. Hellmut Augustin, whose working groups are located at DKFZ and at Medical Faculty Mannheim of the University of Heidelberg. "However, as the role of Ang-2 was not entirely clear yet, we first needed to gain a better understanding of its molecular mechanism of action."

The scientists in Augustin's group have now found out that epithelial cells at the tip of sprouting capillaries produce large amounts of Ang-2, but not its known receptor, Tie-2. Nevertheless, these cells respond to the signaling molecule. This has prompted researchers to conclude that Ang-2 may also be able to mediate signals to epithelial cells via other surface molecules than Tie-2.

Indeed, the team of vascular experts found in the tip cells of newly sprouting capillaries that Ang-2 can use what are called integrins as alternative receptors. Integrins are membrane proteins common in many cell types, which are involved in many intercellular signaling processes.

"That means that we are dealing with two independent effects," Hellmut Augustin explains. "On the one hand, the already known function as an antagonist of Ang-1 in epithelial cells which produce the Tie-2 receptor and, on the other, the integrin-dependent effect on the capillary tip cells which do not have Tie-2. This also explains why experimental therapies targeting Ang-2 are more successful than those targeting its known receptor, Tie-2. This finding shows that it is double worthwhile to further develop therapies against Ang-2. Thus, we can attack the formation of blood vessels in the tumor from two angles at once."


'/>"/>

Contact: Dr. Sibylle Kohlstaedt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. Drug May Ease Cognitive Effects of Huntingtons
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Gastric Banding Most Effective for Obese Teens
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. YazTalk Warns Women of Life Threatening Side Effects
7. Charging less for more effective treatments could reduce health care costs while improving health
8. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
9. New drug for kidney transplant recipients effective in humans
10. ACR, SBI: Avon Survey Reveals Potentially Deadly Effects of USPSTF Mammography Recommendations
11. Two Sepsis Treatments Look Equally Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under Dr. ... board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program ... delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in ... and decide to donate. , “Women’s Hospital at Renaissance has been a collection ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... at the InterContinental Hotel in Boston, Massachusetts ... will present at 11:20 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
Breaking Medicine Technology: